company background image
PTIX

Protagenic Therapeutics NasdaqCM:PTIX Stock Report

Last Price

US$0.55

Market Cap

US$9.5m

7D

1.4%

1Y

-68.2%

Updated

01 Dec, 2022

Data

Company Financials
PTIX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

PTIX Stock Overview

Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders.

Protagenic Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Protagenic Therapeutics
Historical stock prices
Current Share PriceUS$0.55
52 Week HighUS$1.89
52 Week LowUS$0.52
Beta-0.089
1 Month Change-1.81%
3 Month Change-20.91%
1 Year Change-68.18%
3 Year Changen/a
5 Year Change-68.73%
Change since IPO-96.46%

Recent News & Updates

Recent updates

Shareholder Returns

PTIXUS BiotechsUS Market
7D1.4%2.7%1.4%
1Y-68.2%-10.3%-16.1%

Return vs Industry: PTIX underperformed the US Biotechs industry which returned -10.2% over the past year.

Return vs Market: PTIX underperformed the US Market which returned -14.8% over the past year.

Price Volatility

Is PTIX's price volatile compared to industry and market?
PTIX volatility
PTIX Average Weekly Movement9.5%
Biotechs Industry Average Movement11.2%
Market Average Movement7.4%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market3.3%

Stable Share Price: PTIX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: PTIX's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/an/an/ahttps://www.protagenic.com

Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York.

Protagenic Therapeutics, Inc. Fundamentals Summary

How do Protagenic Therapeutics's earnings and revenue compare to its market cap?
PTIX fundamental statistics
Market CapUS$9.46m
Earnings (TTM)-US$3.84m
Revenue (TTM)n/a

0.0x

P/S Ratio

-2.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
PTIX income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$3.84m
Earnings-US$3.84m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.22
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio4.3%

How did PTIX perform over the long term?

See historical performance and comparison